Citations

Showing 10 of 108135 citations.

Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance
Chen, Justin Anthony , Roskin, Krishna M. , Arber, Daniel A. , Bangs, Charles D., Cherry, Athena M. , Ewalt, Mark D. , Frésard, Laure , Kearney, Hutton M. , Ohgami, Robert S. , Pearce, Kathryn E., Merker, Jason D. , Roskin, Krishna M , Arber, Daniel A , Cherry, Athena M , Ewalt, Mark D , Fire, Andrew Z , Fresard, Laure , Kearney, Hutton M , Montgomery, Stephen B , Ohgami, R S , Pitel, Beth A , Merker, Jason D , Gotlib, Jason , Hou, Yanli , Baughn, Linda B. , Montgomery, Stephen B. , Pitel, Beth A. , Gotlib, Jason

Mayo Clinic

Blood Advances | September 10, 2021 | Volume: 5 | Issue: 17 | Pages: 3492-3496

10.1182/bloodadvances.2020004174 | PMID 34505882 Get It

Abstract The basis for acquired resistance to JAK inhibition in patients with JAK2-driven hematologic malignancies is not well understood. We report a patient with a myeloproliferative neoplasm (MPN) with a BCR activator of RhoGEF and GTPase (BCR)–JAK2 fusion with initial hematologic response to ruxolitinib who rapidly developed B-lymphoid blast transformation. We analyzed pre-ruxolitinib and blast transformation samples using genome sequencing, DNA mate-pair sequencing (MPseq), RNA sequencing (RNA-seq), and chromosomal microarray to characterize possible mechanisms of resistance. No resistance mutations in the BCR-JAK2 fusion gene or transcript were identified, and fusion transcript expression levels remained stable. However, at the time of blast transformation, MPseq detected a new IKZF1 copy-number loss, which is predicted to result in loss of normal IKZF1 protein translation. RNA-seq revealed significant upregulation of genes negatively regulated by IKZF1, including IL7R and CRLF2. Disease progression was also characterized by adaptation to an activated B-cell receptor (BCR)–like signaling phenotype, with marked upregulation of genes such as CD79A, CD79B, IGLL1, VPREB1, BLNK, ZAP70, RAG1, and RAG2. In summary, IKZF1 deletion and a switch from cytokine dependence to activated BCR-like signaling phenotype represent putative mechanisms of ruxolitinib resistance in this case, recapitulating preclinical data on resistance to JAK inhibition in CRLF2-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia.
Practice-Changing Opportunity to Reduce Disparities in Screening Mammography—Implementation of Risk Assessment in Primary Care
Valencia, Elizabeth , Pruthi, Sandhya , Valencia, Elizabeth M

Mayo Clinic

JAMA Network Open | September 10, 2021 | Volume: 4 | Issue: 9 | Pages: e2124535

10.1001/jamanetworkopen.2021.24535 | PMID 34505890 Get It

Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement
Herrmann, Joerg , Lenihan, Daniel J. , Armenian, Saro H. , Barac, Ana , Blaes, Anne , Cardinale, Daniela , Carver, Joseph R. , Dent, Susan , Ky, Bonnie , Lyon, Alexander R. , Fradley, Michael G. , Ganatra, Sarju , Curigliano, Giuseppe , Mitchell, Joshua D. , Minotti, Giorgio , Lang, Ninian N. , Liu, Jennifer E. , Neilan, Tomas G. , O’Quinn, Rupal, Pusic, Iskra , Porter, Charles , Reynolds, Kerry L. , Ruddy, Kathryn J. , Valent, Peter , Lenihan, Daniel , Armenian, Saro H , Carver, Joseph , López-Fernández, Teresa , Fradley, Michael G , Ganatra, Sarju , Curigliano, Giuseppe , Mitchell, Joshua D , Minotti, Giorgio , Lang, Ninian N , Nohria, Anju , Porter, Charles , Thavendiranathan, Paaladinesh , Barac, Ana , Blaes, Anne H , Ky, Bonnie , Valent, Peter , Lyon, Alexander R , López‐Fernández, Teresa , Dent, Susan

Mayo Clinic

European Heart Journal | September 10, 2021 | Volume: 43 | Issue: 4 | Pages: 280-299

10.1093/eurheartj/ehab674 | PMID 34904661 Get It

Abstract The discipline of Cardio-Oncology has seen tremendous growth over the past decade. It is devoted to the cardiovascular (CV) care of the cancer patient, especially to the mitigation and management of CV complications or toxicities of cancer therapies, which can have profound implications on prognosis. To that effect, many studies have assessed CV toxicities in patients undergoing various types of cancer therapies; however, direct comparisons have proven difficult due to lack of uniformity in CV toxicity endpoints. Similarly, in clinical practice, there can be substantial differences in the understanding of what constitutes CV toxicity, which can lead to significant variation in patient management and outcomes. This document addresses these issues and provides consensus definitions for the most commonly reported CV toxicities, including cardiomyopathy/heart failure and myocarditis, vascular toxicity, and hypertension, as well as arrhythmias and QTc prolongation. The current document reflects a harmonizing review of the current landscape in CV toxicities and the definitions used to define these. This consensus effort aims to provide a structure for definitions of CV toxicity in the clinic and for future research. It will be important to link the definitions outlined herein to outcomes in clinical practice and CV endpoints in clinical trials. It should facilitate communication across various disciplines to improve clinical outcomes for cancer patients with CV diseases.
Latent Factor Structure of Outcome Measures Used in the HABIT® Mild Cognitive Impairment Intervention Programs
DeFeis, Brittany , Ying, Gelan , Kurasz, Andrea M. , Wit, Liselotte De , Amofa, Priscilla , Chandler, Melanie , Shandera‐Ochsner, Anne L., Phatak, Vaishali , Locke, Dona, Shandera-Ochsner, Anne, De Wit, Liselotte , Locke, Dona E.C. , Smith, Glenn E.

Mayo Clinic

Journal of Alzheimer's Disease | September 10, 2021 | Volume: 84 | Issue: 1 | Pages: 193-205

10.3233/jad-210582 | PMID 34511501 Get It

Background: In Alzheimer’s disease and related disorders (ADRD) research, common outcome measures include cognitive and functional impairment, as well as persons with mild cognitive impairment (pwMCI) and care partner self-reported mood and quality of life. Studies commonly analyze these measures separately, which potentially leads to issues of multiple comparisons and/or multicollinearity among measures while ignoring the latent constructs they may be measuring. Objective: This study sought to examine the latent factor structure of a battery of 12-13 measures of domains mentioned above, used in a multicomponent behavioral intervention (The HABIT® program) for pwMCI and their partners. Methods: Exploratory factor analysis (EFA) involved 214 pwMCI-partner pairs. Subsequent Confirmatory factor analyses (CFA) used 730 pairs in both pre- and post-intervention conditions. Results: EFA generated a three-factor model. Factors could be characterized as partner adjustment (29.9%), pwMCI adjustment (18.1%), and pwMCI impairment (12.8%). The subsequent CFA confirmed our findings, and the goodness-of-fit for this model was adequate in both the pre- (CFI = 0.937; RMSEA = 0.057, p = 0.089) and post-intervention (CFI = 0.942; RMSEA = 0.051, p = 0.430) groups. Conclusion: Results demonstrated a stable factor structure across cohorts and intervention conditions suggesting that three broad factors may provide a straightforward and meaningful model to assess intervention outcome, at least during the MCI phase of ADRD.
Changes in the vasculature of human brain tumors: Implications for treatment
Zhang, Wenjuan , Elmquist, William F. , Elmquist, William F , Zhang, Wenjuan , Talele, Surabhi , Sarkaria, Jann N.

Mayo Clinic

Neuro-Oncology | September 10, 2021 | Volume: 23 | Issue: 12 | Pages: 1995-1997

10.1093/neuonc/noab220 | PMID 34515316 Get It

Neutralizing a Springboard for Inflammation: Physical Activity to Control the Immune Network
Kallen, Victor , Scherder, Rogier, Cramer, Maarten J., Stam, J. , Johnson, Bruce D. , Scherder, Erik , Stam, Jacqueline

Mayo Clinic

Healthcare | September 10, 2021 | Volume: 9 | Issue: 9 | Pages: 1196

10.3390/healthcare9091196 | PMID 34574970 Get It

The severe consequences of the present Corona Virus Disease 2019 COVID-19 pandemic seem to be closely related to an already ongoing (‘first’) pandemic, directly associated with a sedentary lifestyle. It seems evident that the prognosis after infection is substantially worse for individuals suffering from, for example, (visceral) obesity, cardiovascular disease, and diabetes type 2. Consequently, it may be considered highly relevant to gain insight into the potential beneficial effects of exercise interventions to strengthen the immune system, particularly in high-risk populations. For this reason, the exercise protocols that are suggested to strengthen the immune system, which can be executed by all ages and almost all physical conditions, were reviewed and evaluated. Previously published protocols range from interrupting prolonged sitting, to regular low-to-moderate exercise activities, to high intensity, typically interval, sports formats. Reported positive effects on immune functioning appear to be induced either directly or via beneficial metabolic and/or psychological effects and become measurable after 3 weeks to 3 months. Based in these findings, it appeared possible to design an optimal exercise protocol to maximize effects on immune functioning that should be executable for all, even under restricted (‘lockdown’) circumstances.
Variable differences of nerve conduction amplitudes versus velocities and distal latencies of healthy subjects assessed in ethnic cohorts
Alhammad, Reem , Davies, Jenny , Litchy, William J. , Carter, Rickey E. , Dyck, P. James B. , Dyck, Peter J., Dyck, Peter J., Carter, Rickey, Carter, Rickey E , Dyck, Peter J., Dyck, Peter J.

Mayo Clinic

Muscle & Nerve | September 10, 2021 | Volume: 65 | Issue: 2 | Pages: 162-170

10.1002/mus.27418 | PMID 34505719 Get It

Abstract Variable differences of nerve conduction amplitudes vs velocities and distal latencies (DLs) of healthy subjects assessed in ethnic cohorts. Introduction/Aims The variables affecting reference compound muscle (CMAP) and sensory nerve action potential (SNAP) amplitudes as compared to ones affecting conduction velocities and DLs have not been adequately evaluated in previous studies. In this report, this subject is studied in healthy subject cohorts mainly of Northern European extraction, Northern Plains Indians, and Latinos. Methods Nineteen variables and 18 attributes of nerve conductions (NCs) were assessed using highly standard testing conditions and techniques. Classification and Regression Tree analyses were used to assess variable differences among amplitudes, conduction velocities, and DLs. Results The most important variable affecting CMAP and SNAP amplitudes was age. For conduction velocities (CVs) and DLs, the variables were height, ethnic cohort, and age. Discussion The variables affecting attributes of NCs were similar for the three ethnic cohorts evaluated. The differences of variables affecting amplitudes compared to CVs and DLs need to be taken into account in interpretation of NC results and in setting reference limits for use in medical practice, epidemiology surveys, and therapeutic trials. Scores of CMAP and SNAP amplitudes are suitable measures of sensorimotor polyneuropathy severity, whereas conduction velocities and DLs reflect physiologic/pathologic abnormality of nerve fibers.
Assessing the rate, natural history, and treatment trends of intracranial aneurysms in patients with intracranial dural arteriovenous fistulas: a Consortium for Dural Arteriovenous Fistula Outcomes Research (CONDOR) investigation
Abecassis, Isaac Josh, Meyer, R. Michael, Levitt, Michael R. , Sheehan, Jason P. , Gross, Bradley A. , Lockerman, Ashley, Brinjikji, Waleed , Starke, Robert M. , Chen, Stephanie H. , Potgieser, Adriaan R. E., Dijk, J. Marc C. van , Durnford, Andrew , Bulters, Diederik , Satomi, Junichiro, Tada, Yoshiteru , Kwasnicki, Amanda , Amin‐Hanjani, Sepideh , Alaraj, Ali , Hayakawa, M. , Derdeyn, Colin P. , Winkler, Ethan A. , Abla, Adib A. , Guniganti, Ridhima , Kansagra, Akash P. , Zipfel, Gregory J. , Kim, Louis J. , _, _, _, _, Piccirillo, Jay F. , Vine, Roanna , Cloft, Harry J. , Kallmes, David F. , Pollock, Bruce E. , Link, Michael J., Patibandla, Mohana Rao, Buell, Thomas J. , Paisan, Gabriella, Kelly, Cory , Duffill, Jonathan, Ditchfield, Adam, Millar, John S. , Macdonald, Jason, Polifka, Adam , Laurent, Dimitri , Lunsford, L. Dade , Jankowitz, Brian T. , Guerrero, Waldo R. , McGruder, Allen, Charbel, Fady T. , Aletich, Victor , Rose‐Finnell, Linda, Peterson, Eric C. , Yavagal, Dileep R. , Sur, Samir , Kanematsu, Yasuhisa , Kinouchi, T. , Korai, Masaaki , Yamaguchi, Izumi , Yamamoto, Yuki , Lawton, Michael T. , Rutkowski, Martin J. , Aziz‐Sultan, Mohammad Ali , Patel, Nirav , Frerichs, Kai U., Levitt, Michael R , Amin-Hanjani, Sepideh , Alaraj, Ali , van DijK, J Marc C , Abla, Adib , Bulters, Diederik O , Derdeyn, Colin P , Chen, Ching‐Jen , Gross, Bradley , Fox, W Christopher , Lanzino, Giuseppe , Samaniego, Edgar A , Lai, Pui Man Rosalind , Du, Rose , Kim, Louis J. , _, _, _, _, Raman, Hari S. , Lipsey, Kim L. , Giordan, Enrico , Link, Michael J. , Ding, Dale , Hoh, Brian L. , Smith, Jessica , Ortega-Gutierrez, Santiago , Hasan, David , Roa, Jorge A. , Rossen, James D. , Yamamoto, Nobuaki , Phelps, Ryan

Mayo Clinic

Journal of Neurosurgery | September 10, 2021 | Volume: 136 | Issue: 4 | Pages: 971-980

10.3171/2021.1.jns202861 | PMID 34507300 Get It

OBJECTIVE There is a reported elevated risk of cerebral aneurysms in patients with intracranial dural arteriovenous fistulas (dAVFs). However, the natural history, rate of spontaneous regression, and ideal treatment regimen are not well characterized. In this study, the authors aimed to describe the characteristics of patients with dAVFs and intracranial aneurysms and propose a classification system. METHODS The Consortium for Dural Arteriovenous Fistula Outcomes Research (CONDOR) database from 12 centers was retrospectively reviewed. Analysis was performed to compare dAVF patients with (dAVF+ cohort) and without (dAVF-only cohort) concomitant aneurysm. Aneurysms were categorized based on location as a dAVF flow-related aneurysm (FRA) or a dAVF non–flow-related aneurysm (NFRA), with further classification as extra- or intradural. Patients with traumatic pseudoaneurysms or aneurysms with associated arteriovenous malformations were excluded from the analysis. Patient demographics, dAVF anatomical information, aneurysm information, and follow-up data were collected. RESULTS Of the 1077 patients, 1043 were eligible for inclusion, comprising 978 (93.8%) and 65 (6.2%) in the dAVF-only and dAVF+ cohorts, respectively. There were 96 aneurysms in the dAVF+ cohort; 10 patients (1%) harbored 12 FRAs, and 55 patients (5.3%) harbored 84 NFRAs. Dural AVF+ patients had higher rates of smoking (59.3% vs 35.2%, p < 0.001) and illicit drug use (5.8% vs 1.5%, p = 0.02). Sixteen dAVF+ patients (24.6%) presented with aneurysm rupture, which represented 16.7% of the total aneurysms. One patient (1.5%) had aneurysm rupture during follow-up. Patients with dAVF+ were more likely to have a dAVF located in nonconventional locations, less likely to have arterial supply to the dAVF from external carotid artery branches, and more likely to have supply from pial branches. Rates of cortical venous drainage and Borden type distributions were comparable between cohorts. A minority (12.5%) of aneurysms were FRAs. The majority of the aneurysms underwent treatment via either endovascular (36.5%) or microsurgical (15.6%) technique. A small proportion of aneurysms managed conservatively either with or without dAVF treatment spontaneously regressed (6.2%). CONCLUSIONS Patients with dAVF have a similar risk of harboring a concomitant intracranial aneurysm unrelated to the dAVF (5.3%) compared with the general population (approximately 2%–5%) and a rare risk (0.9%) of harboring an FRA. Only 50% of FRAs are intradural. Dural AVF+ patients have differences in dAVF angioarchitecture. A subset of dAVF+ patients harbor FRAs that may regress after dAVF treatment.
Dural arteriovenous fistulas without cortical venous drainage: presentation, treatment, and outcomes
Samaniego, Edgar A., Roa, Jorge A., Hayakawa, Minako, Chen, Ching-Jen, Sheehan, Jason P., Kim, Louis J., Abecassis, Isaac Josh, Levitt, Michael R., Guniganti, Ridhima, Kansagra, Akash P., Lanzino, Giuseppe, Giordan, Enrico, Brinjikji, Waleed, Bulters, Diederik, Durnford, Andrew, Fox, W. Christopher, Polifka, Adam J., Gross, Bradley A., Amin-Hanjani, Sepideh, Alaraj, Ali, Kwasnicki, Amanda, Starke, Robert M., Sur, Samir, Dijk, J. Marc C. van, Potgieser, Adriaan R. E., Satomi, Junichiro, Tada, Yoshiteru, Abla, Adib, Winkler, Ethan, Du, Rose, Lai, Pui Man Rosalind, Zipfel, Gregory J., Derdeyn, Colin P., _, _, _, _, Zipfel, Gregory J., Kansagra, Akash P., Guniganti, Ridhima, Piccirillo, Jay F., Raman, Hari, Lipsey, Kim, Lanzino, Giuseppe, Giordan, Enrico, Brinjikji, Waleed, Vine, Roanna, Cloft, Harry J., Kallmes, David F., Pollock, Bruce E., Link, Michael J., Sheehan, Jason, Chen, Ching-Jen, Patibandla, Mohana Rao, Ding, Dale, Buell, Thomas, Paisan, Gabriella, Kim, Louis J., Levitt, Michael R., Abecassis, Isaac Josh, Meyer, R. Michael, Kelly, Cory, Bulters, Diederik, Durnford, Andrew, Duffill, Jonathan, Ditchfield, Adam, Millar, John, Macdonald, Jason, Fox, W. Christopher, Polifka, Adam J., Laurent, Dimitri, Hoh, Brian, Smith, Jessica, Lockerman, Ashley, Gross, Bradley A., Lunsford, L. Dade, Jankowitz, Brian T., Hayakawa, Minako, Derdeyn, Colin P., Samaniego, Edgar A., Gutierrez, Santiago Ortega, Hasan, David, Roa, Jorge A., Rossen, James, Guerrero, Waldo, McGruder, Allen, Amin-Hanjani, Sepideh, Alaraj, Ali, Kwasnicki, Amanda, Charbel, Fady T., Aletich, Victor A., Rose-Finnell, Linda, Dijk, J. Marc C. van, Potgieser, Adriaan R. E., Starke, Robert M., Peterson, Eric C., Yavagal, Dileep R., Sur, Samir, Chen, Stephanie H., Satomi, Junichiro, Tada, Yoshiteru, Kanematsu, Yasuhisa, Yamamoto, Nobuaki, Kinouchi, Tomoya, Korai, Masaaki, Yamaguchi, Izumi, Yamamoto, Yuki, Abla, Adib, Winkler, Ethan, Phelps, Ryan R. L., Lawton, Michael, Rutkowski, Martin, Du, Rose, Lai, Pui Man Rosalind, Aziz-Sultan, M. Ali, Patel, Nirav, Frerichs, Kai U., Derdeyn, Colin P. , Amin‐Hanjani, Sepideh , Bulters, Diederik , Aziz‐Sultan, Mohammad Ali , Levitt, Michael R. , Hayakawa, M. , Alaraj, Ali , Dijk, J. Marc C. van , Abla, Adib A. , Korai, Masaaki , Lai, Pui Man Rosalind , Levitt, Michael R , Amin-Hanjani, Sepideh , Alaraj, Ali , van DijK, J Marc C , Abla, Adib , Lai, Rosalind , Bulters, Diederik O , Derdeyn, Colin P , Samaniego, Edgar A., Roa, Jorge A., Hayakawa, Minako, Chen, Ching-Jen, Sheehan, Jason P., Kim, Louis J., Abecassis, Isaac Josh, Levitt, Michael R., Guniganti, Ridhima, Kansagra, Akash P., Lanzino, Giuseppe, Giordan, Enrico, Brinjikji, Waleed, Durnford, Andrew, Fox, W. Christopher, Polifka, Adam J., Gross, Bradley A., Kwasnicki, Amanda, Starke, Robert M., Sur, Samir, Dijk, J. Marc C. van, Potgieser, Adriaan R. E., Satomi, Junichiro, Tada, Yoshiteru, Winkler, Ethan, Du, Rose, Lai, Pui Man Rosalind, Zipfel, Gregory J., _, _, _, _, Zipfel, Gregory J., Kansagra, Akash P., Guniganti, Ridhima, Piccirillo, Jay F., Raman, Hari, Lipsey, Kim, Lanzino, Giuseppe, Giordan, Enrico, Brinjikji, Waleed, Vine, Roanna, Cloft, Harry J., Kallmes, David F., Pollock, Bruce E., Link, Michael J., Sheehan, Jason, Chen, Ching-Jen, Patibandla, Mohana Rao, Ding, Dale, Buell, Thomas, Paisan, Gabriella, Kim, Louis J., Abecassis, Isaac Josh, Meyer, R. Michael, Kelly, Cory, Bulters, Diederik, Durnford, Andrew, Duffill, Jonathan, Ditchfield, Adam, Millar, John, Macdonald, Jason, Fox, W. Christopher, Polifka, Adam J., Laurent, Dimitri, Hoh, Brian, Smith, Jessica, Lockerman, Ashley, Gross, Bradley A., Lunsford, L. Dade, Jankowitz, Brian T., Hayakawa, Minako, Derdeyn, Colin P., Samaniego, Edgar A., Gutierrez, Santiago Ortega, Hasan, David, Roa, Jorge A., Rossen, James, Guerrero, Waldo, McGruder, Allen, Amin-Hanjani, Sepideh, Alaraj, Ali, Kwasnicki, Amanda, Charbel, Fady T., Aletich, Victor A., Rose-Finnell, Linda, Dijk, J. Marc C. van, Potgieser, Adriaan R. E., Starke, Robert M., Peterson, Eric C., Yavagal, Dileep R., Sur, Samir, Chen, Stephanie H., Satomi, Junichiro, Tada, Yoshiteru, Kanematsu, Yasuhisa, Yamamoto, Nobuaki, Kinouchi, Tomoya, Yamaguchi, Izumi, Yamamoto, Yuki, Abla, Adib, Winkler, Ethan, Phelps, Ryan R. L., Lawton, Michael, Rutkowski, Martin, Du, Rose, Lai, Pui Man Rosalind, Patel, Nirav, Frerichs, Kai U.

Mayo Clinic

Journal of Neurosurgery | September 10, 2021 | Volume: 136 | Issue: 4 | Pages: 942-950

10.3171/2021.1.jns202825 | PMID 34507278 Get It

OBJECTIVE Current evidence suggests that intracranial dural arteriovenous fistulas (dAVFs) without cortical venous drainage (CVD) have a benign clinical course. However, no large study has evaluated the safety and efficacy of current treatments and their impact over the natural history of dAVFs without CVD. METHODS The authors conducted an analysis of the retrospectively collected multicenter Consortium for Dural Arteriovenous Fistula Outcomes Research (CONDOR) database. Patient demographics and presenting symptoms, angiographic features of the dAVFs, and treatment outcomes of patients with Borden type I dAVFs were reviewed. Clinical and radiological follow-up information was assessed to determine rates of new intracranial hemorrhage (ICH) or nonhemorrhagic neurological deficit (NHND), worsening of venous hyperdynamic symptoms (VHSs), angiographic recurrence, and progression or spontaneous regression of dAVFs over time. RESULTS A total of 342 patients/Borden type I dAVFs were identified. The mean patient age was 58.1 ± 15.6 years, and 62% were women. The mean follow-up time was 37.7 ± 54.3 months. Of 230 (67.3%) treated dAVFs, 178 (77%) underwent mainly endovascular embolization, 11 (4.7%) radiosurgery alone, and 4 (1.7%) open surgery as the primary modality. After the first embolization, most dAVFs (47.2%) achieved only partial reduction in early venous filling. Multiple complementary interventions increased complete obliteration rates from 37.9% after first embolization to 46.7% after two or more embolizations, and 55.2% after combined radiosurgery and open surgery. Immediate postprocedural complications occurred in 35 dAVFs (15.2%) and 6 (2.6%) with permanent sequelae. Of 127 completely obliterated dAVFs by any therapeutic modality, 2 (1.6%) showed angiographic recurrence/recanalization at a mean of 34.2 months after treatment. Progression to Borden-Shucart type II or III was documented in 2.2% of patients and subsequent development of a new dAVF in 1.6%. Partial spontaneous regression was found in 22 (21.4%) of 103 nontreated dAVFs. Multivariate Cox regression analysis demonstrated that older age, NHND, or severe venous-hyperdynamic symptoms at presentation and infratentorial location were associated with worse prognosis. Kaplan-Meier curves showed no significant difference for stable/improved symptoms survival probability in treated versus nontreated dAVFs. However, estimated survival times showed better trends for treated dAVFs compared with nontreated dAVFs (288.1 months vs 151.1 months, log-rank p = 0.28). This difference was statistically significant for treated dAVFs with 100% occlusion (394 months, log-rank p < 0.001). CONCLUSIONS Current therapeutic modalities for management of dAVFs without CVD may provide better symptom control when complete angiographic occlusion is achieved.
Intervention for unruptured high-grade intracranial dural arteriovenous fistulas: a multicenter study
Chen, Ching-Jen, Buell, Thomas J., Ding, Dale, Guniganti, Ridhima, Kansagra, Akash P., Lanzino, Giuseppe, Giordan, Enrico, Kim, Louis J., Levitt, Michael R., Abecassis, Isaac Josh, Bulters, Diederik, Durnford, Andrew, Fox, W. Christopher, Polifka, Adam J., Gross, Bradley A., Hayakawa, Minako, Derdeyn, Colin P., Samaniego, Edgar A., Amin-Hanjani, Sepideh, Alaraj, Ali, Kwasnicki, Amanda, Dijk, J. Marc C. van, Potgieser, Adriaan R. E., Starke, Robert M., Sur, Samir, Satomi, Junichiro, Tada, Yoshiteru, Abla, Adib A., Winkler, Ethan A., Du, Rose, Lai, Pui Man Rosalind, Zipfel, Gregory J., Sheehan, Jason P., _, _, _, _, Zipfel, Gregory J., Kansagra, Akash P., Guniganti, Ridhima, Piccirillo, Jay F., Raman, Hari, Lipsey, Kim, Lanzino, Giuseppe, Giordan, Enrico, Brinjikji, Waleed, Vine, Roanna, Cloft, Harry J., Kallmes, David F., Pollock, Bruce E., Link, Michael J., Sheehan, Jason, Chen, Ching-Jen, Patibandla, Mohana Rao, Ding, Dale, Buell, Thomas, Paisan, Gabriella, Kim, Louis J., Levitt, Michael R., Abecassis, Isaac Josh, Meyer, R. Michael, Kelly, Cory, Bulters, Diederik, Durnford, Andrew, Duffill, Jonathan, Ditchfield, Adam, Millar, John, Macdonald, Jason, Fox, W. Christopher, Polifka, Adam J., Laurent, Dimitri, Hoh, Brian, Smith, Jessica, Lockerman, Ashley, Gross, Bradley A., Lunsford, L. Dade, Jankowitz, Brian T., Hayakawa, Minako, Derdeyn, Colin P., Samaniego, Edgar A., Gutierrez, Santiago Ortega, Hasan, David, Roa, Jorge A., Rossen, James, Guerrero, Waldo, McGruder, Allen, Amin-Hanjani, Sepideh, Alaraj, Ali, Kwasnicki, Amanda, Charbel, Fady T., Aletich, Victor A., Rose-Finnell, Linda, Dijk, J. Marc C. van, Potgieser, Adriaan R. E., Starke, Robert M., Peterson, Eric C., Yavagal, Dileep R., Sur, Samir, Chen, Stephanie H., Satomi, Junichiro, Tada, Yoshiteru, Kanematsu, Yasuhisa, Yamamoto, Nobuaki, Kinouchi, Tomoya, Korai, Masaaki, Yamaguchi, Izumi, Yamamoto, Yuki, Abla, Adib, Winkler, Ethan, Phelps, Ryan R. L., Lawton, Michael, Rutkowski, Martin, Du, Rose, Lai, Pui Man Rosalind, Aziz-Sultan, M. Ali, Patel, Nirav, Frerichs, Kai U., Derdeyn, Colin P. , Amin‐Hanjani, Sepideh , Bulters, Diederik , Aziz‐Sultan, Mohammad Ali , Giordan, Enrico , Levitt, Michael R. , Ding, Dale , Hayakawa, M. , Alaraj, Ali , Dijk, J. Marc C. van , Abla, Adib A. , Korai, Masaaki , Lai, Pui Man Rosalind , Levitt, Michael R , Ding, Dale , Amin-Hanjani, Sepideh , Alaraj, Ali , van DijK, J Marc C , Abla, Adib , Lai, Rosalind , Bulters, Diederik O , Derdeyn, Colin P , Chen, Ching-Jen, Buell, Thomas J., Ding, Dale, Guniganti, Ridhima, Kansagra, Akash P., Lanzino, Giuseppe, Kim, Louis J., Abecassis, Isaac Josh, Bulters, Diederik, Durnford, Andrew, Fox, W. Christopher, Polifka, Adam J., Gross, Bradley A., Hayakawa, Minako, Derdeyn, Colin P., Samaniego, Edgar A., Alaraj, Ali, Kwasnicki, Amanda, Dijk, J. Marc C. van, Potgieser, Adriaan R. E., Starke, Robert M., Sur, Samir, Satomi, Junichiro, Tada, Yoshiteru, Abla, Adib A., Winkler, Ethan A., Du, Rose, Lai, Pui Man Rosalind, Zipfel, Gregory J., Sheehan, Jason P., _, _, _, _, Zipfel, Gregory J., Kansagra, Akash P., Guniganti, Ridhima, Piccirillo, Jay F., Raman, Hari, Lipsey, Kim, Lanzino, Giuseppe, Giordan, Enrico, Brinjikji, Waleed, Vine, Roanna, Cloft, Harry J., Kallmes, David F., Pollock, Bruce E., Link, Michael J., Sheehan, Jason, Chen, Ching-Jen, Patibandla, Mohana Rao, Ding, Dale, Buell, Thomas, Paisan, Gabriella, Kim, Louis J., Levitt, Michael R., Abecassis, Isaac Josh, Meyer, R. Michael, Kelly, Cory, Durnford, Andrew, Duffill, Jonathan, Ditchfield, Adam, Millar, John, Macdonald, Jason, Fox, W. Christopher, Polifka, Adam J., Laurent, Dimitri, Hoh, Brian, Smith, Jessica, Lockerman, Ashley, Gross, Bradley A., Lunsford, L. Dade, Jankowitz, Brian T., Hayakawa, Minako, Samaniego, Edgar A., Gutierrez, Santiago Ortega, Hasan, David, Roa, Jorge A., Rossen, James, Guerrero, Waldo, McGruder, Allen, Amin-Hanjani, Sepideh, Kwasnicki, Amanda, Charbel, Fady T., Aletich, Victor A., Rose-Finnell, Linda, Dijk, J. Marc C. van, Potgieser, Adriaan R. E., Starke, Robert M., Peterson, Eric C., Yavagal, Dileep R., Sur, Samir, Chen, Stephanie H., Satomi, Junichiro, Tada, Yoshiteru, Kanematsu, Yasuhisa, Yamamoto, Nobuaki, Kinouchi, Tomoya, Yamaguchi, Izumi, Yamamoto, Yuki, Abla, Adib, Winkler, Ethan, Phelps, Ryan R. L., Lawton, Michael, Rutkowski, Martin, Du, Rose, Lai, Pui Man Rosalind, Patel, Nirav, Frerichs, Kai U.

Mayo Clinic

Journal of Neurosurgery | September 10, 2021 | Volume: 136 | Issue: 4 | Pages: 962-970

10.3171/2021.1.jns202799 | PMID 34608140 Get It

OBJECTIVE The risk-to-benefit profile of treating an unruptured high-grade dural arteriovenous fistula (dAVF) is not clearly defined. The aim of this multicenter retrospective cohort study was to compare the outcomes of different interventions with observation for unruptured high-grade dAVFs. METHODS The authors retrospectively reviewed dAVF patients from 12 institutions participating in the Consortium for Dural Arteriovenous Fistula Outcomes Research (CONDOR). Patients with unruptured high-grade (Borden type II or III) dAVFs were included and categorized into four groups (observation, embolization, surgery, and stereotactic radiosurgery [SRS]) based on the initial management. The primary outcome was defined as the modified Rankin Scale (mRS) score at final follow-up. Secondary outcomes were good outcome (mRS scores 0–2) at final follow-up, symptomatic improvement, all-cause mortality, and dAVF obliteration. The outcomes of each intervention group were compared against those of the observation group as a reference, with adjustment for differences in baseline characteristics. RESULTS The study included 415 dAVF patients, accounting for 29, 324, 43, and 19 in the observation, embolization, surgery, and SRS groups, respectively. The mean radiological and clinical follow-up durations were 21 and 25 months, respectively. Functional outcomes were similar for embolization, surgery, and SRS compared with observation. With observation as a reference, obliteration rates were higher after embolization (adjusted OR [aOR] 7.147, p = 0.010) and surgery (aOR 33.803, p < 0.001) and all-cause mortality was lower after embolization (imputed, aOR 0.171, p = 0.040). Hemorrhage rates per 1000 patient-years were 101 for observation versus 9, 22, and 0 for embolization (p = 0.022), surgery (p = 0.245), and SRS (p = 0.077), respectively. Nonhemorrhagic neurological deficit rates were similar between each intervention group versus observation. CONCLUSIONS Embolization and surgery for unruptured high-grade dAVFs afforded a greater likelihood of obliteration than did observation. Embolization also reduced the risk of death and dAVF-associated hemorrhage compared with conservative management over a modest follow-up period. These findings support embolization as the first-line treatment of choice for appropriately selected unruptured Borden type II and III dAVFs.